Angiotensin II type 1 receptor (AGTR1); estrogen receptor; HER2 (ERBB2; neu) BriefCommunication Pages: 932 - 932
Polo-like kinase 1 (PLK1; STPK13); anaphase promoting complex subunit 1 (ANAPC1); ANAPC4 BriefCommunication Pages: 935 - 935
Serine/threonine kinase 33 (STK33); ribosomal protein S6 kinase, polypeptide 1 (RPS6KB1; S6K1) BriefCommunication Pages: 936 - 936
Syk tyrosine kinase (SYK); macrophage stimulating 1 receptor, c-met-related tyrosine kinase (MST1R; RON) BriefCommunication Pages: 937 - 937
Endothelial cell nitric oxide synthase 3 (NOS3; eNOS); protein kinase cGMP-dependent type 1 (PRKG1; PKG1) BriefCommunication Pages: 940 - 940
Calcium channel voltage-dependent T-type α1G subunit (CACNA1G; Cav3.1) BriefCommunication Pages: 941 - 941
NLR family pyrin domain containing 1 (NLRP1; NALP1); NLRP3 (NALP3) BriefCommunication Pages: 947 - 947
Granulocyte macrophage colony-stimulating factor receptor (CSF2RA; CD116) BriefCommunication Pages: 951 - 951
Transgenic marmoset-based disease models with germline transmission BriefCommunication Pages: 957 - 957
Saccharide-sensitive mesoporous silica nanoparticles for drug delivery BriefCommunication Pages: 958 - 958
Engineering botulinum toxin to target non-neuronal cells to broaden therapeutic applications BriefCommunication Pages: 959 - 959